c-Myc tag Peptide (A6003): Mechanism, Benchmarks & Applications

Executive Summary: The c-Myc tag Peptide (A6003) is a precisely synthesized reagent corresponding to amino acids 410–419 of human c-Myc, used for displacing c-Myc-tagged fusion proteins from anti-c-Myc antibodies in immunoassays (APExBIO). It offers high specificity for antibody inhibition, supporting robust immunoassay workflows (see mechanistic review). The c-Myc protein is a proto-oncogene, acting as a transcription factor in cell proliferation, apoptosis, and differentiation (Wu et al., 2021). The peptide is soluble at ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water with sonication, providing workflow versatility. APExBIO supplies c-Myc tag Peptide (SKU A6003) for research use only; it is not for diagnostic or clinical application.

Biological Rationale

The c-Myc gene (MYC) encodes a nuclear transcription factor essential for regulating cell cycle progression, growth, apoptosis, and stem cell maintenance (Wu et al., 2021). Overexpression or dysregulation of c-Myc is frequently observed in hematological and solid tumors, confirming its proto-oncogenic status. c-Myc forms heterodimers with Max to bind E-box sequences, activating transcription of genes involved in ribosome biogenesis and protein synthesis. It upregulates cyclins (cell cycle progression) and downregulates p21 (cell cycle inhibition) and Bcl-2 (apoptosis regulation), amplifying proliferative signals. Research tools that modulate c-Myc detection or activity, such as the c-Myc tag Peptide, are pivotal for dissecting oncogenic networks and immune signaling pathways in cancer biology (see comparative workflow article).

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide is a synthetic 10-amino-acid sequence, identical to residues 410–419 (EQKLISEEDL) of the human c-Myc protein (APExBIO). In immunoassays, this peptide competitively binds anti-c-Myc monoclonal antibodies, displacing c-Myc-tagged fusion proteins from antibody complexes. This displacement is used to elute or release c-Myc-tagged constructs from immunoaffinity matrices. The specificity is conferred by the exact sequence match between the peptide and the antibody epitope, allowing high-fidelity immunodetection and elution workflows. The tag sequence does not interfere with the biological function of the fusion protein or introduce cytotoxicity, provided it is not overexpressed in live-cell applications.

Evidence & Benchmarks

• The c-Myc tag sequence (EQKLISEEDL) enables high-affinity binding to anti-c-Myc antibodies, facilitating efficient displacement in immunoassays (APExBIO).
• c-Myc activation upregulates cyclin genes and ribosomal biogenesis, impacting cellular proliferation in cancer models (Wu et al., 2021).
• Peptide solubility is ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (with sonication); ethanol is unsuitable due to insolubility (APExBIO).
• Specificity of the c-Myc tag system has been validated in comparative immunoassay workflows, with minimal cross-reactivity reported (practical workflow review).
• c-Myc tag Peptide does not directly modulate endogenous c-Myc transcription factor function or downstream signaling in cellular models (mechanistic insights).

Applications, Limits & Misconceptions

Key Applications:

• Displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibody matrices in immunoprecipitation (IP) and affinity purification workflows.
• Competitive inhibition controls in ELISA and Western blot assays for validation of antibody specificity.
• Optimization of cell signaling and transcription factor assays in cancer research, particularly in studies focused on MYC gene amplification (advanced mechanisms article—this article clarifies quantitative solubility and workflow boundaries).

Limits:

• Not suitable for in vivo therapeutic use or diagnostic applications; intended for research use only.
• Does not inhibit endogenous c-Myc protein or alter transcription factor activity in living cells.
• Requires desiccated storage at -20°C; peptide solutions are unstable upon long-term storage.

Common Pitfalls or Misconceptions

• The c-Myc tag Peptide is not a c-Myc pathway inhibitor; it does not reduce endogenous c-Myc levels or activity.
• Direct addition of peptide to cell cultures does not modulate c-Myc-driven transcriptional programs.
• Peptide is insoluble in ethanol; improper solvent use can lead to precipitation and loss of function.
• Overuse in immunoassays may saturate antibodies, leading to non-specific elution.
• Not validated for diagnostic, clinical, or therapeutic workflows.

Workflow Integration & Parameters

The c-Myc tag Peptide is typically reconstituted in DMSO or water (with sonication) to achieve stock concentrations of ≥60.17 mg/mL or ≥15.7 mg/mL, respectively (APExBIO). For immunoprecipitation, the peptide is added at a final concentration of 0.2–1 mg/mL (buffer pH 7.4, 4°C, 10–30 min) to elute c-Myc-tagged proteins from antibody-conjugated beads. Optimal elution should be empirically determined to minimize non-specific release. For ELISA inhibition controls, concentrations between 0.5–2 μg/mL are standard. Peptide solutions should be freshly prepared; avoid repeated freeze-thaw cycles. Store lyophilized peptide desiccated at -20°C. The A6003 kit is workflow-compatible with common anti-c-Myc monoclonal antibodies and matrices. For troubleshooting and comparative benchmarks, see this detailed review (this article updates product-specific solubility and storage data).

Conclusion & Outlook

The c-Myc tag Peptide (A6003) from APExBIO is a validated reagent for specific displacement of c-Myc-tagged proteins in immunoaffinity workflows, supporting high-fidelity detection and purification. Its precise sequence identity, high solubility in DMSO/water, and stability characteristics make it widely adaptable for cancer biology, transcription factor regulation, and immunoassay optimization. However, its use is strictly limited to research contexts; it does not function as a direct cell signaling modulator. Ongoing innovations focus on integrating synthetic tag peptides with multiplexed detection systems and next-generation antibody technologies, further advancing mechanistic dissection of proto-oncogene networks in cellular and cancer biology (Wu et al., 2021).